Open AccessExpression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival
Author(s) -
Katarzyna Kapelko-Słowik,
Donata UrbaniakKujda,
Dariusz Wołowiec,
Bożena Jaźwiec,
Jarosław Dybko,
Jacek Jakubaszko,
Mirosław Słowik,
Kazimierz Kuliczkowski
Publication year - 2013
Publication title -
postępy higieny i medycyny doświadczalnej
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.275
H-Index - 34
eISSN - 1732-2693
pISSN - 0032-5449
DOI - 10.5604/17322693.1052449
Subject(s) - myeloid leukemia , leukemia , oncogene , medicine , cancer research , pim1 , bone marrow , myeloid , oncology , biology , cancer , serine , cell cycle , phosphorylation , biochemistry
PIM-2 is a proto-oncogene that encodes for a serine/threonine kinase that interacts with various signaling molecules. PIM-2 is highly expressed in neoplastic tissues and in leukemic and lymphoma cell lines, which is consistent with its role during oncogenic transformation. The nuclear factor kappa B (NF-κB) pathway appears to be deregulated in a variety of tumors, with sustained activity of NF-κB leading to apoptotic resistance in tumor cells. The aim of this study was to investigate whether expression of PIM-2 and NF-κB is altered in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).